Therapeutic combination by T cells with anti-CD19 and anti-chimeric antigen receptors for maturation of relapsed or refractory multiple myeloma B cells

被引：0
|
作者：
Stocker, Nicolas
机构：
来源：
HEMATOLOGIE | 2019年 / 25卷 / 06期
关键词：
D O I：
10.1684/hma.2019.1502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [1] Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Heng, Gang
    Jia, Jiankun
    Li, Shiqi
    Fu, Gang
    Wang, Meiling
    Qin, Dabing
    Li, Yunyan
    Pei, Li
    Tian, Xiaobo
    Zhang, Jiasi
    Wu, Yi
    Xiang, Shali
    Wan, Jia
    Zhu, Wei
    Zhang, Pei
    Zhang, Qianzhen
    Peng, Xi
    Wang, Linling
    Wang, Ping
    Wei, Zhihao
    Zhang, Yingzi
    Wang, Guiqin
    Chen, Xue
    Zhang, Chengcheng
    Sun, Yanni
    Zhao, Wenxu
    Fan, Yahan
    Yang, Zhi
    Chen, Jieping
    Qian, Cheng
    CLINICAL CANCER RESEARCH, 2020, 26 (07) : 1606 - 1615
  • [2] Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
    Kochenderfer, James N.
    Rosenberg, Steven A.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (05) : 267 - 276
  • [3] Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
    James N. Kochenderfer
    Steven A. Rosenberg
    Nature Reviews Clinical Oncology, 2013, 10 : 267 - 276
  • [4] Comparison of single infusion of anti-BC-MA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma
    葛娇
    China Medical Abstracts(Internal Medicine), 2022, 39 (01) : 59 - 60
  • [5] Sequential treatment with anti-CD19 and CD22 chimeric antigen receptor T cells in children with relapsed or refractory B acute lymphoblastic leukemia
    Chanut, Mathilde
    HEMATOLOGIE, 2023, 29 (06): : 332 - 334
  • [6] Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
    Cao, Yaqing
    Lu, Wenyi
    Sun, Rui
    Jin, Xin
    Cheng, Lin
    He, Xiaoyuan
    Wang, Luqiao
    Yuan, Ting
    Lyu, Cuicui
    Zhao, Mingfeng
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [7] Treatment of Chemotherapy-Refractory B-Cell Malignancies with Anti-CD19 Chimeric Antigen Receptor T Cells
    Kochenderfer, James N.
    Kassim, Sadik H.
    Somerville, Robert
    Dudley, Mark E.
    Carpenter, Robert O.
    Lu, Lily
    Feldman, Steven A.
    Morton, Kathleen E.
    Toomey, Mary Ann
    Rosenberg, Steven A.
    MOLECULAR THERAPY, 2014, 22 : S295 - S295
  • [8] The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
    Cao, Jun-Xia
    Gao, Wei-Jian
    You, Jia
    Wu, Li-Hua
    Liu, Jin-Long
    Wang, Zheng-Xu
    CYTOTHERAPY, 2019, 21 (07) : 769 - 781
  • [9] A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
    Yan, Zhiling
    Cao, Jiang
    Cheng, Hai
    Qiao, Jianlin
    Zhang, Huanxin
    Wang, Ying
    Shi, Ming
    Lan, Jianping
    Fei, Xiaoming
    Jin, Lai
    Jing, Guangjun
    Sang, Wei
    Zhu, Feng
    Chen, Wei
    Wu, Qingyun
    Yao, Yao
    Wang, Gang
    Zhao, Jing
    Zheng, Junnian
    Li, Zhenyu
    Xu, Kailin
    LANCET HAEMATOLOGY, 2019, 6 (10): : E521 - E529
  • [10] Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia
    Huang, Liang
    Wang, Na
    Li, Chunrui
    Cao, Yang
    Xiao, Yi
    Xiao, Min
    Zhang, Yicheng
    Zhang, Tongcun
    Zhou, Jianfeng
    BLOOD, 2017, 130
12345